One Substance, Multiple Legal Realities: Classification Cascades in the Psychedelic Medicine Transition
Zenodo (CERN European Organization for Nuclear Research) April 19, 2026 H. Tamba
Psilocybin currently holds six contradictory legal classifications across different jurisdictions, including Schedule I in the US, Breakthrough Therapy designation from the FDA, legal therapeutic use in Oregon and Colorado, Schedule 8 medical use in Australia, and pending rescheduling review. This fragmentation creates a classification cascade—a disruption propagating through administrative, clinical, and economic channels. Analysis of 44 regulatory events across 21 countries (1992–2025) shows a sharp inflection after the 2018 FDA Breakthrough Therapy Designation. Psilocybin-depression research grew at 58.6% annually (2015–2025), and total psilocybin publications increased 54-fold from 12 (2000) to 656 (2025).